STOCK TITAN

Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Perceptive Advisors LLC, together with related entities and Joseph Edelman, reports beneficial ownership of 12,046,579 shares of Solid Biosciences Inc. common stock, representing 11.2% of the class. This percentage is based on 107,365,171 shares of common stock, including 139,933 shares issuable upon vested options held by Adam Stone.

The holding is primarily through Perceptive Life Sciences Master Fund, Ltd., which directly holds 11,833,539 common shares and 8,912,655 pre-funded warrants exercisable at $0.001 per share, subject to a 9.99% Beneficial Ownership Limitation that currently prevents any warrant exercise. Perceptive Xontogeny Venture Fund, LP directly holds 73,107 shares. Adam Stone holds options for 217,433 shares, of which 139,933 are exercisable within 60 days; the Master Fund is entitled to receive director compensation from his board service via a management fee offset.

Positive

  • None.

Negative

  • None.
Beneficial ownership 12,046,579 shares Total shares beneficially owned by reporting persons
Ownership percentage 11.2% Percent of Solid Biosciences common stock class
Shares used for ownership base 107,365,171 shares Common stock including 139,933 option shares as of referenced dates
Master Fund common shares 11,833,539 shares Common stock directly held by Perceptive Life Sciences Master Fund, Ltd.
Pre-funded warrants 8,912,655 warrants Pre-funded warrants exercisable at $0.001 per share, subject to 9.99% cap
Warrant exercise price $0.001 per share Exercise price of pre-funded warrants for Solid Biosciences common stock
Venture Fund common shares 73,107 shares Common stock directly held by Perceptive Xontogeny Venture Fund, LP
Adam Stone options 217,433 shares (139,933 exercisable) Stock options held; exercisable portion included in ownership base
pre-funded warrants financial
"8,912,655 pre-funded warrants (the "Pre-Funded Warrants") immediately exercisable"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Limitation financial
"subject to the Beneficial Ownership Limitation (as defined below)"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
beneficially own financial
"the Reporting Persons would beneficially own, as determined in accordance"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
management fee offset financial
"board service through a partial management fee offset"
Schedule 13D regulatory
"may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d)"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

FAQ

How much of Solid Biosciences Inc. (SLDB) does Perceptive Advisors report owning?

Perceptive Advisors and related parties report beneficial ownership of 12,046,579 shares of Solid Biosciences common stock, representing 11.2% of the outstanding class, based on 107,365,171 shares of common stock as of the referenced dates.

What securities does Perceptive Life Sciences Master Fund hold in Solid Biosciences (SLDB)?

Perceptive Life Sciences Master Fund directly holds 11,833,539 shares of Solid Biosciences common stock and 8,912,655 pre-funded warrants, each immediately exercisable at $0.001 per share, subject to a 9.99% Beneficial Ownership Limitation that currently blocks any warrant exercise.

What is the Beneficial Ownership Limitation disclosed for SLDB pre-funded warrants?

The pre-funded warrants held by the Master Fund include a 9.99% Beneficial Ownership Limitation, meaning they cannot be exercised if it would cause the reporting persons to beneficially own more than 9.99% of Solid Biosciences’ outstanding common stock after the exercise.

How many Solid Biosciences (SLDB) shares does Perceptive Xontogeny Venture Fund hold?

Perceptive Xontogeny Venture Fund, LP directly holds 73,107 shares of Solid Biosciences common stock, which represents approximately 0.1% of the class based on 107,365,171 shares of common stock used for the ownership calculation.

What share count underlies the 11.2% ownership reported in the SLDB Schedule 13D/A?

The 11.2% beneficial ownership is calculated using 107,365,171 Solid Biosciences common shares, comprising 107,225,238 shares outstanding as of August 4, 2026 plus 139,933 shares issuable upon vested options held by Adam Stone.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





83422E204

(CUSIP Number)
Perceptive Advisors LLC
Alexander Rakitin, 51 Astor Place, 10th Floor
New York, NY, 10003
646-205-5345

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
06/30/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:08/14/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2026
Perceptive Xontogeny Venture Fund, LP
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2026